News

With its comprehensively revised, reorganised and updated course on SGLT-2 inhibitors, launched today, EASD e-Learning signals a new phase in the learning platform’s development.

A new study reported in Diabetologia looks at the risk factors for developing diabetes among a cohort of pregnant women after giving birth. The research shows that decline in beta cell function is ranked as ...

Recent research suggests that there is much more to obesity than elevated body mass index. The latest findings on the role of liver fat and metabolically healthy obesity were under discussion at the 59th Ann...

Factors other than hyperglycaemia influence complications for both mother and baby in a pregnancy affected by type 1 diabetes. New metabolomic findings from the CONCEPTT trial, reported in Diabetologia, shed...

The benefits of SGLT-2 inhibitors for people with type 2 diabetes and chronic kidney disease (CKD) have been amply demonstrated in recent years. So is it time to prescribe them to all those who have both con...

A number of drugs that mimic or enhance incretin agonism are now being used for glucose lowering in diabetes. They have proven cardiovascular safety and may even reduce cardiovascular complications. A new re...

The latest research into hypoglycaemia was under discussion at the 59th Annual Meeting of the EASD. The ‘To hell with the hypo’ session covered topics ranging from a tool to predict nocturnal hyp...

A new population-based study, reported in a recent issue of Diabetologia, uses confocal microscopy to show that dysfunctional glucose metabolism is linked to corneal neurodegeneration. The findings suggest t...

Disparities in health burdens were explored at the American Diabetes Association’s 83rd Scientific Sessions. Lisa Buckingham reports. 

Glucagon-like peptide-1 agonists have improved outcomes for people with type 2 diabetes in recent years with their glucose-lowering and weight-loss effects. This has fuelled interest in the therapeutic poten...

What are the barriers to technology use in primary care and how can we overcome them? This question was addressed at the American Diabetes Association’s 83rd Scientific Sessions. Lisa Buckingham report...

As rates of heart disease in diabetes fall thanks to improved prevention and treatment, cancer is coming to prominence as a complication and cause of excess death. However, a new paper in Diabetes Care repor...

As research increasingly focuses on the early stages of type 1 diabetes, a presentation at the American Diabetes Association’s 83rd Scientific Sessions covered the emerging data on the potential of phy...

The timing of moderate-to-vigorous exercise has an impact on HbA1c, with the afternoon hours being more favourable. This aspect of lifestyle intervention comes from the Look AHEAD trial in type 2 diabetes an...

Intermittent fasting (IF) has gained popularity as a way of losing weight and improving cardiometabolic health. A debate on whether the window for eating within an IF regime is best timed early or late in th...

While the recent 100th anniversary of the discovery of insulin was widely acknowledged in the diabetes community, much less attention has been paid to the centenary of its vital counter-regulatory hormo...

With an ageing population, it’s increasingly important to understand the impact of diabetes on older adults. Hypoglycaemia was the focus at the American Diabetes Association’s 83rd Scientific Ses...

In the latest module from EASD e-Learning, the second in its ‘Lifestyle intervention’ course, Professors Richard Bracken and Dominik Pesta home in on the theory and practice of exercise...

A new review in Diabetologia looks at how genetic risk scores are already being applied, both at the pre-clinical stages of type 1 diabetes and to more accurate classification of type 1, type 2 and other for...

The microbiome is the latest research frontier in obesity and the latest studies – and future speculation – were under discussion at the recent American Diabetes Association’s 83rd Sci...

A new study in Diabetologia finds that people with type 2 diabetes who are socioeconomically disadvantaged are less likely to be prescribed incretin-based therapies, including GLP-1 receptor agonists, even t...